Demeetra AgBio Acquires Hera BioLabs

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Agilent Technologies Acquires BIOVECTRA for $925M

July 22, 2024

Pharmaceuticals

Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.

Aeglea BioTherapeutics Acquires Spyre Therapeutics

June 22, 2023

Biotechnology

Aeglea BioTherapeutics completed a stock-for-stock acquisition of Spyre Therapeutics, a privately held biotechnology company advancing antibody therapeutics for inflammatory bowel disease (IBD). Concurrent with the acquisition Aeglea announced a $210 million PIPE led by Fairmount Funds to advance Spyre’s pipeline (lead programs SPY001 and SPY002) into clinical studies and fund operations into 2026.

Bruker Corporation Acquires biocrates life sciences ag

June 3, 2025

Biotechnology

Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.

Sartorius Stedim Biotech Acquires Polyplus

April 13, 2023

Biotechnology

Sartorius Stedim Biotech agreed to acquire Strasbourg-based Polyplus (Polyplus‑transfection S.A.) for €2.4 billion, pending customary regulatory approvals. The transaction buys the business from private equity backers including ARCHIMED and Warburg Pincus and strengthens Sartorius’s cell & gene therapy reagent and upstream bioprocessing portfolio.

Eurofins Discovery Acquires DiscoveryBioMed

July 5, 2022

Biotechnology

Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.